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doi:10.1016/j.jfma.2011.06.014Background/Purpose: The clinical analyses and prognoses of mitochondrial diseases with
A3243G mutation are rarely documented in Taiwan. Our study investigated the clinical pheno-
types and the outcomes of patients with mitochondrial disease and the A3243G mutation of
mtDNA in a Taiwanese population, and compared these with previous reports.
Methods: We retrospectively studied 22 consecutive patientswithmitochondrial disease and the
A3243Gmutation ofmtDNA in ChangGungMemorial Hospital between 1988 and 2009. All patients
underwent a detailed demographic registration, neurological examinations, amuscle biopsy, and
mitochondrial DNA analysis. Modified Rankin scale, the presence of recurrent strokes or seizures,
critical medical complications, and death were monitored during the follow-up period.
Results: Of the 22 patients, seizures and stroke-like episodes were found in 12 (55%). Visceral
involvement, including cardiomyopathy, nephropathy, and pulmonary hypertension, were noted
in five patients (23%). Patients with seizures had a high frequency of status epilepticus (92%) and
a younger age of onset (21.3  7.2 years). Both the KaplaneMeier survival analysis and the
Cox-regression model showed a marked deterioration in patients with seizures after 7 years of
follow-up.
Conclusion: Our study found that seizures and status epilepticus are the most important predic-
tive values for a poor outcome in patients with the mtA3243G mutation of mtDNA. Age of onset
and visceral organ involvement had no prominent influence on the prognosis. Some medical
complications could be well controlled or even reversed after management.
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mM of each dNTP, 40 pmol of each oligonucleotide primer,The clinical spectrum, survival rates, and long-term func-
tional outcome for mitochondrial diseases (MID) have been
studied in pediatric patients. The mortality rates were
found to range from 46% to 57% and were higher in neonatal
onset, visceral involvement, and Leigh disease.1,2 Mito-
chondrial encephalomyopathy, lactic acidosis, and stroke-
like episodes (MELAS) is a well-known disease that is most
commonly associated with the A3243G mutation of mito-
chondrial DNA (mtDNA) in Chinese populations.3 The
proportion of mutant mtDNA, cardiomyopathy, and the age
at which the first symptoms appeared are predictors of
mortality in MID patients.1 One previous study also showed
a trend of a worse prognosis in MID patients with seizures or
stroke-like episodes.4 However, clinical analyses of patients
with the A3243G mutation of mtDNA remain scarce.
Patients and methods
Twenty-two patients with symptomatic mitochondrial
disease with the A3243G mutation of mtDNA were retro-
spectively reviewed in Chang Gung Memorial Hospital from
1988 to 2009. The diagnosis was based on the clinical
features, muscle biopsy, and genetic findings. Demographic
data, including sex and age at onset, and clinical features
of myopathy, neuropathy, stroke-like episodes, seizures,
status epilepticus (SE), diabetes, chronic progressive
external ophthalmoplegia (CPEO), ataxia, parkinsonism,
dystonia, myoclonus, and lactate concentration, were ob-
tained. The definition of SE is based on the duration of
a continuous generalized convulsion for more than 30
minutes or of recurrent seizures without a return of
consciousness. The significant symptoms/signs of visceral
involvement, including cardiomyopathy, nephropathy, and
pulmonary hypertension, were also evaluated.
Muscle biopsy study
An open biopsy was performed from the vastus lateralis or
the biceps muscles of the MID patients. The biopsy speci-
mens were prepared for histopathological studies, including
staining with hematoxylin and eosin (H&E), modified
Gomori trichrome, nicotinamide adenine dinucleotide
(NADH)-tetrazolium reductase, succinate dehydrogenase
(SDH), and cytochrome c oxidase (CCO). The presence of
ragged red fibers over 2% of all fibers is defined as mito-
chondrial myopathy.5
Molecular genetic analysis
Total DNA from muscle biopsy specimens of the patients
was obtained by methods described previously.6,7 A
molecular analysis was performed using the restriction
endonuclease Apa I. A DNA fragment of 1159 base pairs (bp)
encompassing the putative mutation site (nucleotide posi-
tion 3243) was amplified by polymerase chain reaction
(PCR) using a pair of primers, H2678-2696 and L3817-3836.6
The A3243G mutation in the mtDNA creates an additional
Apa I site in this region.8 The PCR was performed on a Per-
kin-Elmer/Cetus DNA thermal cycler (Norwalk, CT, USA) in100 ml of a reaction mixture containing 200 ng of DNA, 200
two units of Taq DNA polymerase, 50 mM KCl, 1.5 mM MgCl2,
10 mM tris-HCl (pH 8.8 at 25C) and 0.01% (w/v) gelatin.
The reaction mixture was subjected to 30 cycles of PCR
with the following thermal profile: denaturation at 94C for
40 seconds, annealing at 56 C for 40 seconds, and exten-
sion at 72C for 40 seconds. To quantify the amount of
mutant mtDNA by PCR-restriction fragment length poly-
morphism (PCR-RFLP), 1 ml of -33P-dATP (10 mCi/ml;
Amersham, Buckinghamshire, UK) was added to the reac-
tion mixture in the final cycle before carrying out the
restriction analyses. The digested PCR product was then
subjected to agarose gel electrophoresis, and the gel was
dried and exposed to an X-ray film (Amersham) or subjected
to analysis by a PhosphorImager (Molecular Dynamics,
Sunnyvale, CA, USA). The bands on the X-ray film or the
images on the PhosphorImager were then quantified by
densitometry using ImageQuaNT (Molecular Dynamics).
Prognosis and follow-up
The median follow-up duration was 8.5 years (range, 2e27
years). Brain image studies, including computed tomog-
raphy and/or magnetic resonance imaging, were conducted
for detecting asymptomatic stroke-like episodes. Modified
Rankin scale (MRS) and the presence of recurrent stroke,
seizure episodes, or death were registered. MRS scores of
more than 3 were defined as markedly deteriorated. A poor
prognosis predicted a marked deterioration or mortality,
whereas a favorable prognosis indicated functional inde-
pendency (MRS 0e3).
Statistical analysis
SPSS 17.0 (SPSS, Chicago, IL, USA) was used for statistical
analysis. Categorical variables were compared by c2 or
Fisher’s exact test. Two-sample t tests or ManneWhitney
tests were used to compare unpaired groups. The prognosis
was compared between subgroups by using the
KaplaneMeier survival analysis and log-rank test. Factors
that might affect the prognosis were analyzed by a multi-
variate Cox-regression model. A p value < 0.05 was
considered to be statistically significant.
This study was approved by the Human Studies of Insti-
tutional Review Board in our hospital.
Results
The clinical features and demographic data of our 22
patients with symptomatic mitochondrial disease with the
A3243G mutation of mtDNA are summarized in Table 1. The
patients comprised 11 men and 11 women, with a mean
onset age of 27.5 14.8 years (range, 8e55 years).
Of the 22 patients, diabetes mellitus was noted in nine
(41%). Stroke-like episodes were found in 12 (55%) patients,
while seizures were reported in 12 patients (55%). The
mean age at occurrence of the first stroke was 30.7 12.6
years, and the median frequency of patients with stroke-
like episodes was two. The mean onset age of the first
seizure was 25.1 9.7 years. Status epilepticus was noted
Table 1 Demographics of 22 Taiwanese patients with mitochondriopathies and mtA3243G mutation of mtDNA.
Patient Basic data Follow-up (y) Clinical manifestations Prognosis
Sex Onset
age (y)
Neu Str Seizure SE CPEO Ata Dys Pm Myo DM Cp Ne PHT LA Age of
MaD (y)
Age of
death (y)
1 F 46 2 þ þ (2)     þ  þ þ     Expired 47 48
2 F 31 4  þ (2) þ þ          þ Expired 34 35
3 F 19 4  þ (2) þ þ     þ  þ þ  þ Expired 23 23
4 M 54 2  þ (2)        þ    þ Expired 54 55
5 F 31 4 þ  þ þ      þ    NA Expired NA 37
6 F 17 7  þ (4) þ þ          þ Expired NA 25
7 M 22 2 þ þ (3) þ þ          þ Expired NA 29
8 M 12 7 þ þ (4) þ þ þ         þ Expired NA 19
9 M 24 4 þ  þ þ           Expired NA 28
10 F 16 8  þ (1) þ þ          þ Expired 24 24
11 M 13 12  þ (2) þ þ      þ    þ Expired 24 25
12 F 53 2 þ         þ    NA Expired NA 55
13 M 32 12  þ (2) þ þ þ      þ   þ MaD 45
14 M 14 12 þ þ (3) þ þ      þ    þ MaD 28
15 F 40 10 þ     þ    þ     Stationary
16 M 6 9           þ   þ Stationary
17 M 38 12  þ (2)        þ þ   NA Stationary
18 F 23 17        þ þ      Stationary
19 M 24 27 þ  þ           NA Stationary
20 M 27 10     þ        þ þ Stationary
21 F 55 9          þ     Stationary
22 F 8 15               Stationary
Numbers in parentheses indicate numbers of stroke-like episodes.
þ Z presence; e Z absence; Ata Z ataxia; Cp Z cardiomyopathy; CPEO Z chronic progressive external ophthalmoplegia; DM Z iabetes; Dys Z dystonia; F Z female; LA Z lactic
acidosis; MZmale; MaDZ markedly deteriorated; MyoZ myoclonus; NAZ not available; NepZ nephropathy; NeuZ neuropathy HTZ pulmonary hypertension; PmZ parkinsonism;
SE Z status epilepticus; Str Z stroke-like episodes.
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492 C.-H. Liu et al.in every patient with both seizures and poor prognosis (11
patients; 50%), but was absent in the only patient with
seizures who showed a favorable outcome. Three patients
(14%) presented with involuntary movements, including
myoclonus, dystonia, or parkinsonism. Chronic progressive
external ophthalmoplegia was noticed in three patients
(14%). Of the patients with visceral involvement, cardio-
myopathy was noted in three (14%). Nephropathy and
pulmonary hypertension were recorded in only one case.
Lactic acidosis was found in 12 of 18 (67%) recorded
patients. Full-blown MELAS syndrome was developed in
nine of 22 patients (41%) throughout the follow-up period.
The other mitochondrial syndromes including KearnseSayre
syndrome, myoclonic epilepsy with ragged-red fiber, Leb-
er’s hereditary optic neuropathy, and Leigh syndrome were
not noted.
Fourteen patients underwent a muscle biopsy during the
hospital course; only 50% of them presented clinical
pictures of myopathies. Thirteen of the 14 patients (93%)
showed numerous ragged-red fibers in modified Gomori
trichrome stain.
All 22 patients had a point mutation at 3243 mtDNA in
the blood sample analyses. In addition, the other mutations
such as 8344 and 11778 point mutation were not found. The
amounts of mutant mtDNA compared with wild type mtDNA
(heteroplasmy) in the blood and muscle samples were
measured in only 12 patients (55%). The mean proportions
of mtDNA of the A3243G mutation were 72 20.5 % (range,
41e92%) in the muscle and 44.7 22.7% (range, 20e80%) in
the blood.
During the follow-up period, 14 of 22 patients (64%) had
a poor prognosis, including 12 who died and two who were
severely disabled. Eight patients (36%) remained function-
ally independent at the last outpatient visit. The mean age
of onset in patients with a poor prognosis was 27.4 14.9
years. Eleven of the 12 patients with seizures eventually
developed status epilepticus. Nine of the 11 patients (82%)
with status epilepticus died, and two (18%) had severe
functional impairments. A higher frequency (79%) of seizure
attacks was noted in the poor prognosis group compared to
the frequency (13%) in the favorable prognosis group. Nine
patients (75%) who presented with ischemic strokes died,Figure 1 (A) KaplaneMeier analysis (p Z 0.05) and (B) Cox-regre
chondrial encephalomyopathy, lactic acidosis, and stroke-like episoand two (17%) had severe functional impairments. All of the
nine patients who experienced both strokes and seizures
either died or were severely disabled. Only one of seven
(14%) patients who developed neither strokes nor seizures
died, as a result of diabetic complications. One patient
with cardiomyopathy remained stable after a long-term
follow-up. One patient with severe pulmonary hyperten-
sion remained independent in performing daily activities.
One patient with nephropathy suffered from intractable
hyperkalemia, chronic renal failure, and seizures, yet
survived for 4 years. However, her condition deteriorated
after her first stroke-like episode. She finally died because
of complicated sepsis.
The presence of seizure attacks, especially status epi-
lepticus, may predict the poor prognosis in our patients
(odds ratio, 25.7; p< 0.05). Patients with stroke-like
episodes showed a worse outcome than those without
stroke-like episodes (odds ratio, 25.7; p< 0.05). Patients
who developed a full-blown MELAS syndrome had a worse
prognosis compared to those who were nonsyndromic
(p< 0.05). Poor prognosis was measured in the groups with
or without seizures, and the difference between the two
groups is illustrated in the KaplaneMeier survival analysis
(Fig. 1A). We found no statistical difference in poor prog-
nosis probability based on the onset age of initial symp-
toms, lactic acidosis, diverse neurologic signs [neuropathy,
parkinsonism, ataxia, dystonia, myoclonus, and chronic
progressive external ophthalmoplegia (CPEO)], or visceral
involvements (cardiomyopathy, nephropathy, and pulmo-
nary hypertension) (Table 2).
In patients with seizure episodes, status epilepticus was
noted in 11 of the 12 patients (92%), and all of these
patients showed a poor prognosis. The only patient without
status epilepticus remained functionally independent. The
age of onset of symptoms was lower in patients with
seizures than in patients without seizures (21.3 7.2 vs.
35.0 18.3, p< 0.05). The prevalence of strokes was
higher in patients with seizures (75% vs. 30%). However,
strokes remained a risk factor dependent on seizure attacks
(pZ 0.08). Presence of lactic acidosis also showed a higher
frequency in patients with seizures (90% vs. 38%, p< 0.05).
Using a Cox-regression model to exclude the interference ofssion model (p < 0.05), showing marked deterioration in mito-
des (MELAS) patients with seizure after 7 years of follow-up.
Table 2 Risk factors of poor prognosis in Taiwanese
mitochondrial disease patients.
Favorable
prognosis
(n Z 8)
Poor prognosis
(n Z 14)
p
Sex (male:female) 4:4 7:7
Age of onset (y) 27.6 14.5 27.4 14.5 0.98
Seizures 1/8 11/14 <0.01
Stroke-like episode 1/8 11/14 <0.01
Stroke and seizure 0/8 9/14 <0.01
Statue epilepticus 0/8 11/14 <0.01
Neuropathy 2/8 8/14 0.2
Myopathy 2/8 8/14 0.2
Diabetes 3/8 6/14 1.0
Ataxia 1/8 0/14 0.36
Dystonia 0/8 1/14 1.0
Myoclonus 1/8 0/14 1.0
Parkinsonism 1/8 2/14 0.36
Cardiomyopathy 2/8 2/14 0.6
Nephropathy 0/8 1/14 1.0
Pulmonary
hypertension
1/8 0/14 0.36
Visceral organ 3/8 2/14 0.31
Lactic acidosis 2/6 10/12 0.11
Prognosis in mitochondrial MELAS disease 493all independent factors, we found that patients with
seizures showed marked deterioration in the clinical course
after 7 years of follow-up (Fig. 1B).
Discussion
Patients with the A3243G mtDNA mutation have a shorter
life expectancy and are prone to death because of cardio-
pulmonary failure or status epilepticus regardless of the
onset age.9 Visceral involvement is a predictor of a poor
outcome in pediatric patients.1 Interestingly, seizure was
the most powerful predicting factor for a poor outcome in
our MID patients. Occurrence of seizures marks a deterio-
ration of the disease course and is difficult to control in
patients with mitochondrial respiratory chain defects with
encephalopathy.10 We also noticed that patients with
seizures showed an unfavorable prognosis whenever they
had status epilepticus or younger age of onset; this asso-
ciation was less commonly mentioned in previous studies.
The factors that provoked the seizure events remained
unclear in this study. In our 12 patients with seizures, only
six (50%) had abnormal brain images including stroke-like
episode or cortical atrophy at the first attack. Lactic
acidosis was more frequent in patients with seizures. We
did not follow the serial changes of lactate concentration at
each seizure attack and therefore we can not conclude
whether lactic acidosis may precipitate seizures in our
patients. Valproic acid should be avoided for seizure
control in patients with the A3243G mutation of mtDNA,
because of the high risk of inducing fulminating liver failure
or aggravating seizure attacks in MID patients.11e13 Four of
our patients received valproic acid for seizure control, with
a mean duration of 2.5 years. Our patients did not developacute hepatitis under valproic acid treatment. It is not
clear whether valproic acid aggravated mitochondrial
dysfunction or resulted in intractable seizures in these
patients. Other anti-epileptic drugs, including phenytoin,
lamotrigine, topiramate, levetiracetam, and oxacarbama-
zepine, were used in the recently diagnosed cases. It
remains uncertain which anti-epileptic drugs are the most
appropriate to use for seizure control in MID patients.14
However, the only patient (Patient 12) receiving a prophy-
lactic anti-epileptic drug (phenytoin) had not had a seizure
attack at the last follow-up.
According to the previous review, patients with stroke-
like episodes should take L-arginine, coenzyme-Q, steroids,
edaravone, creatine monohydrate, or dichloroacetate for
stroke prevention.15 The effect of antiplatelet agents
remains uncertain. In our investigation, all of our 12
patients with stroke showed large or cortical infarctions.
Antiplatelet drugs, including aspirin and clopidogrel, were
used for stroke prevention in 11 patients (92%). However,
recurrent symptomatic strokes were still noted in these 11
patients, suggesting that antiplatelet therapy provided
insufficient prevention in our patients. In contrast to the
previous report,16 none of our patients showed regression
of the stroke-like lesions after seizure control.
Lethal cardiovascular complications, including aortic
rupture, cardiac tamponade, and WolffeParkinsoneWhite
(WPW) syndrome, have been reported previously.17e19
Cardiomyopathy contributed to death in five out of seven
(71%) adult patients with the A3243 G mutation of mtDNA,20
and pediatric patients with cardiomyopathy may have only
an 18% survival rate at 16 years of age.21 A routine cardiac
examination was suggested for patients with the MELAS
syndrome because of a high frequency of left ventricle
involvement.22 However, our patients did not show such high
prevalence as theirs. In our four patients with cardiac
involvement, two had right bundle branch block while the
others had a thickened ventricle wall. Only Patient 13 had
symptomatic dyspnea and pulmonary edema. However, this
patient remained functionally independent until the first
seizure attack. In patients with the A3243G mutation of
mtDNA, nephropathy is commonly observed with a patho-
logical change of glomerulosclerosis, while renal tubular
dysfunction is the most common renal abnormality in MID
with a large-scale deletion of mtDNA.23 Whenever renal
failure develops, dialysis could be effective. Our patient
with chronic renal function impairment (Patient 3) did not
develop life-threatening complications. Her condition
deteriorated after the first stroke-like episode, and she died
as a result of sepsis after being bedridden for a long time.
Pulmonary hypertension is rare in MID patients and may
be related to primary pulmonary arterial hypertension,
portal hypertension, and pulmonary thromboembolism.
This was reported to be irreversible and refractory to nitric
oxide and epoprostenol.24 One patient (Patient 20) showed
severe pulmonary hypertension with tricuspid regurgita-
tion, presumed to be related to severe restrictive lung
disease. A noninvasive ventilator (bi-level positive airway
pressure) provided good symptom control and reversed
both the severity of pulmonary hypertension and tricuspid
regurgitation during a long-term follow-up. In our study,
the age of onset and visceral involvement did not predict
a poor prognosis for patients.
494 C.-H. Liu et al.It is known that measuring the proportion of mutant
mtDNA in muscle biopsies is useful in identifying the
symptomatic patients with mitochondrial encephalomyo-
pathies.4 In this study, the extent of heteroplasmy in
mtDNA was similar to the previous report.4 The fluctuations
in mtDNA heteroplasmy may lead to different clinical
manifestations.25 The correlation between the extent of
heteroplasmy and prognosis remains unclear. In our
patients, the proportions of mutant mtDNA were not
routinely measured especially in those with stationary
condition. Therefore, we had insufficient data to conclude
the predictive value of heteroplasmy in long-term outcome.
Conclusion
Our study found that seizures and status epilepticus have
the most important predictive values for poor prognosis in
adult Taiwanese MID patients with the A3243G mutation of
mtDNA. In contrast to pediatric populations, the age of
onset and visceral organ involvement, including cardiomy-
opathy, nephropathy, and pulmonary hypertension, had no
prominent impact on prognosis. The drugs of choice in
seizure control and stroke prevention need further clinical
investigations.
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